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A B S T R A C T   
Prolactin receptor (PRLR), a type-1 cytokine receptor, is overexpressed in a number of cancer types. It has 
attracted much attention for putative pro-oncogenic roles, which however, remains controversial in some ma-
lignancies. In this study, we reported the localization of PRLR to the Hodgkin’s and Reed-Sternberg (HRS) cells of 
Hodgkin’s lymphoma (HL), a neoplasm of predominantly B cell origin. Immunohistochemistry performed on 5- 
μm thick FFPE sections revealed expression of PRLR in HRS cells. Cellular immunofluorescence experiments 
showed that the HL-derived cell lines, Hs445, KMH2 and L428 overexpressed PRLR. The PRLR immunofluo-
rescent signal was depleted after treating the cell lines with 10 μM of siRNA for 48 h. We also tested whether 
PRLR is involved in the growth of HL, in vitro. One-way analysis of variance (ANOVA) on cell growth data obtain 
from WST-1 cell proliferation assay and trypan blue exclusion assay and hemocytometry showed that siRNA- 
depletion of PRLR expression resulted in decreased growth in all three cell lines. These results offered only a 
short insight into the involvement of PRLR in HL. As a result, further investigation is required to decipher the 
precise role(s) of PRLR in the pathogenesis of HL.   
1. Introduction 
Overexpression of hormone receptors have been reported for a 
number of cancer types, a phenotype that is suspected disease in 
development and progression. One such receptor is the prolactin re-
ceptor (PRLR), a type-1 cytokine receptor, although its putative pro- 
oncogenic roles remain controversial in some malignancies. Over-
expression of PRLR has been reported for a growing list of cancer types 
including cancers of the ovaries (Sundaram et al., 2017), cervix 
(Lopez-Pulido et al., 2013), breasts (Hachim et al., 2016) prostate 
(Sackmann-Sala et al., 2014), colon and rectum (Harbaum et al., 2010). 
In some cancers PRLR overexpression is associated with an adverse 
prognosis (Shemanko, 2016; Taylor et al., 2010). Among lymphomas, 
there is only a paucity of information of PRLR expression. PRLR 
expression has been reported for rat Nb2 T lymphoma cells (Shiu et al., 
1983) and a limited number of human non-Hodgkin’s lymphoma (NHL) 
cell lines, including Daudi cells (Matera et al., 2000). PRL, one of the 
cognate ligands for PRLR, appears to be non-mitogenic to PRLR-positive 
NHL cell lines (Matera et al., 2000). 
Hodgkin’s lymphoma (HL) is a unique B-cell neoplasm characterized 
by giant mononuclear Hodgkin’s and multi-nuclear Reed-Sternberg 
(HRS) cells, which make up less than 1% of the tumor. Previous studies 
showed activated signal transducer and activator transcription 5 
(STAT5) in HRS cells of a subsets of HL patients (Martini et al., 2008) 
and in vitro experiments showed that activation of STAT5 resulted from 
IL-21 interaction with IL-21 R (Scheeren et al., 2008). PRLR activities 
are mediated via JAK2/STAT5 signaling. However, the current status of 
PRLR in HL is largely unknown. Thus, this report gives a brief insight 
into involvement of PRLR in HL. Immunohistochemistry (IHC) analyses 
using two different primary antibodies (an anti-mouse PRLr-ECD– mAb 
1A2B1 and and anti-rabbit PRLR– pAb H-300) showed strong PRLR 
staining in the HRS cells in clinical specimen examined. PRLR immu-
nofluorescent signal detected in cell lines stained with mAb 1A2B1 
antibody, was depleted after treatment with 10 u M of siRNA for 48 h. 
We also tested whether PRLR is involved in the growth of HL, in vitro. 
WST-1 cell proliferation assay and trypan blue exclusion assay and 
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hemocytometry showed that siRNA-knockdown of PRLR expression 
resulted in decreased growth in all lines. To the best of our knowledge, 
this is the first report of PRLR expression in HL. Given reports of 
pro-oncogenic roles of PRLR, further research is warranted to gain in-
sights into the role of PRLR in pathogenesis of HL. 
2. Methods and materials 
2.1. Cell lines and cell cultures 
The human HRS-derived cell lines KMH2 and L428 were obtained 
from the German Collection of Microorganisms and Cell Cultures 
(DSMZ), Department of Human and Animal Cell Cultures, Braunsch-
weig, Germany in April 2017. Hs445 was obtained from the American 
Tissue and Cell Collection –ATCC— (Manassas; VA, USA) in March 
2017. L428 and KMH2 were cultured in RPMI 1640 medium supple-
mented with 10 % heat-inactivated fetal bovine serum (FBS) [Gibco, 
Gaithersburg; MD, USA cat. #: 10437028, lot #: 1623737], 1% L- 
glutamine (Thermo Fisher Scientific, Waltham; MA, USA, cat#: 25030- 
081) and penicillin/streptomycin (Thermo Fisher Scientific, cat #: 
15140148). Culture media Hs445 were similar but contained 20 % heat- 
inactivated FBS. Cells used in these experiments were from early passage 
(L428 and KMH2 passage 3, and Hs445, passage 4) and they were 
treated for mycoplasma and subsequently tested negative as described 
by Uphoff et al. (1992, 2002). All cells were maintained in a humid 
environment of 5% CO2 at 37 ◦C. 
2.2. Immunohistochemistry 
Tissue sections used in this study were purchased from OriGene 
Technologies (Rockville; MD, USA) and from US BioMax (Derwood; MD, 
USA). These companies provided documentation regarding approval of 
tissue for clinical observation. Also, our institution does not require IRB 
approval for studies on tissues procured from commercial sources. IHC 
was carried out on xylene-dewaxed, degraded alcohol (100, 80, 70, 50 
%), PBS (Thermo Fisher Scientific, MA, USA, cat. #: 10010023)-rehy-
drated, 5-μm FFPE tissue sections, as described by Gharbaran et al. 
(2019) with minor modifications. Endogenous peroxidases were 
quenched by incubating the sections in 3% H2O2 solution in PBS for 
10 min followed by rapid washes in PBS at room temperature. Section 
were blocked at room temperature for 2 h with 1% BSA containing 5% 
normal goat serum (Sigma—Aldrich, Saint Luis; MO, USA, cat. #: 
G9023) in PBS, followed by overnight incubation at 4 ◦C, in either a 
mouse monoclonal anti-PRLr-ECD antibody (mAb clone 1A2B1) [Invi-
trogen, Carlsbad; CA, USA—cat. #: 359200, lot #: 1529262A], diluted 
1:100 or a rabbit polyclonal anti-PRLR antibody (pAb H-300) [Santa 
Cruz Biotechnology, Dallas; TX, USA—cat. #: sc-20922, lot #: J1910, 
clone H-300] diluted at 1:200. Signal detection was carried out using an 
LSAB kit according to the manufacturer’s instructions (Agilent DAKO, 
Santa Clara; CA, USA, cat. #: K0672). The sections were counterstained 
with Gill’s hematoxylin (Vector Labs, Burlington; ON, Canada, cat. #: 
H-3401) for 22 s and immediately washed in tap water before mounting 
with VectaMount aqueous mounting media (Vector Labs, cat. #: 
H-5501). Photomicrographs of stained tissues were generated with a 
Leica MC190 HD Camera coupled to a Leica DM2500 microscope (Leica 
Microsystems, Richmond Hill; ON, Canada). Preparation of negative 
controls follows all steps except without incubation in primary antibody. 
2.3. Cellular immunofluorescence 
Cellular immunofluorescence steps were similar to those for IHC 
with some modifications. Cells were adhered to poly-D lysine (Sigma- 
Aldrich, MO, USA cat. #: 27964-99-4) coated number 1 coverslips for 
30 min in a humid chamber at 37 ◦C in 5 % CO2, rinsed 1 × with PBS 
then fixed for 20 min with 3.7 % paraformaldehyde (Electron Micro-
scopy Sciences 15710, Hatfield; PA, USA). Fixed cells were 
permeabilized with 0.1 % PBS-TX100 (Triton X-100 purchased from 
Sigma–Aldrich, MO, US, cat. #: T9284) for 30 min then blocked for 
30 min in 1% normal goat serum followed by incubation in primary 
antibody (mAb 1A2B1) diluted 1:400 in blocking buffer for 1 h. Stained 
cells were mounted in ProLong Gold anti-fade reagent containing DAPI 
(Life Technologies, Carlsbad; CA, USA, cat. #: P36931) and images were 
captured with a CoolSNAP HQ2 CCD camera (Cool SNAP EZ, Photo-
metrics, Tucson; AZ, USA) coupled to a Nikon Ti Eclipse inverted mi-
croscope (Melville, NY, USA). 
2.4. RNA isolation, cDNA, and qPCR 
Total RNA was isolated by Trizol (Life Technologies, Carlsbad; CA, 
USA, cat. # 155960218) according manufacture instructions. cDNA was 
prepared by ProtoScript® II First Strand cDNA Synthesis Kit (New En-
gland BioLabs, Rowley; MA, USA, cat. #: E6300S) according manufac-
turer’s instructions, from 50 ng of RNA per reaction. For qPCR, each 
reaction consisted of 10 ng cDNA, 10 mM primers and 10 μl 2X SYBR 
GreenER™ qPCR SuperMix (Life Technologies, cat. #: 11761-100). 
Reactions were carried out in a MicroAmp Fast Optical 96-Well Reac-
tion Plate on a BioRad Icycler Thermal Cycler. The reaction was per-
formed using the standard mode (initial denaturation at 95 ◦C for 10 min 
followed by 40 cycles of 95 ◦C for 15 s and 60 ◦C for 1 min). Each qPCR 
reaction was done in triplicate. The amount of target mRNA was 
normalized to the expression levels of the housekeeping gene GAPDH. 
GAPDH primer pair were 5′-cat ggc ctc caa gga gta ag-3′ and 5′-agg ggt 
ctac atg gca act g-3′ for forward and reverse sequences, respectively, and 
those for PRLR were 5′-tggtctgaaggggtcaatc-3′ and 5′-cccca-
gagctaaactgcaac-3′ for forward and reverse sequences, respectively. The 
ΔΔCt method was used to calculate the fold-change relative to controls. 
For detection of PRL in parental cell lines by qPCR, the primer for-
ward and reverse sequences were 5′- cat cat cag ctg cca cac -3′ and 5′- cca 
cgt act tcg gtg gac cag -3′, respectively. 
2.5. siRNA knockdown of PRLR expression 
1 × 105 cells/mL cultured in 24-well plates overnight were treated 
with 10 μM of siRNA to PRLR (Dharmacon, CO, USA, cat #: L-006304- 
00-0005–ON-TARGETplus SMARTpool) for 48 h. In brief, siRNA was 
complexed with Lipofectamine RNAiMax (Invitrogen, cat. #: 13778075; 
lot #: 2018673) in Opti-MEM reduced serum media (Gibco, cat. #: 
31985070; lot #: 2003883) in 1 x siRNA buffer (Dharmacon, cat #: B- 
002000-UB-100), before applying to cultured cells. The sequence of 
siRNAs included in the ON-TARGETplus SMARTpool from Dharmacon, 
consists of the following sequences: CCGCUAAACCCUUGGAUUA 
(siRNA J-006304-07), UCAGAUACCUAGUGACUUC (siRNA J-006304- 
08), CACCAUCACUUGAACAGAA (siRNA J-006304-09), and GCAU-
GAAUGUCCAGACUAC (siRNA J-006304-10). In these experiments, 
control cells were treated with scrambled, non-targeted siRNA 
(NT_siRNA) (OriGene Technologies, cat #: SR30004). 
2.6. WST-1 cell proliferation assay 
1 × 105 cells/mL plated in 96-well plates overnight and treated with 
10 μM each of PRLR siRNA for 48 h were incubated in indicated culture 
conditions. Cell growth was assessed with WST-1 cell proliferation assay 
(Roche, Branchburg; NJ, USA, cat #: 11644807001, lot #: 14310400), 
according to manufacturer’s instructions and as described by Gharbaran 
et al. (2019). Absorbance was read at 450 nm on a Synergy H1 Hybrid 
microplate reader (BioTek Instruments, Winooski; VT, USA). Cell 
growth (in percentages, %) was computed as a ratio of either the 
absorbance (A450) of PRLR_siRNA or NT_siRNA-treated and absorbance 
(A450 nm) of untreated control (A450 nm). 
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2.7. Trypan Blue exclusion assay and automated hemocytometry 
Trypan blue exclusion assay was carried out using EVE Automated 
Cell Counter (NanoEntek, Guro-gu; Seoul, South Korea) according to 
manufacturer’s instructions. In brief, 10 μl of cell suspension was mixed 
with 10 μl 0.4 % trypan blue then loaded into counting chamber. 
2.8. Mapping of siRNA to putative PRLR isoforms 
We used a bioinformatics approach to the association of each siRNA 
with specific PRLR isoforms. To do this, we BLAST each of the manu-
facturer’s-derived siRNA sequence against publicly available human 
nucleotide sequences. The list of output for each siRNA was manually 
searched using the “Command + F” search function on an Apple Mac-
book Air (Early 2014), using search terms related to PRLR isoforms: 
transcript variant, delta S1, truncated, intermediate isoform, short iso-
forms, etc. 
2.9. Statistical analyses 
Data analyses were performed using SAS 9.1.3 (SAS Institute Inc., 
Cary; NC, USA) and StatView 5 (SAS Institute Inc.). Absorbance data 
reflecting cell growth were presented as standard error of the mean 
(SEM) derived from triplicates. Analysis of variance (ANOVA) and F 
statistics were used to determine differences between the means as 
defined by p < 0.05. Each experiment was repeated at least three times. 
3. Results 
3.1. Antibodies 
The antibodies used in our study, mAb 1A2B1 and pAb H-300, were 
among six commercial antibodies evaluated for specificity to human 
PRLR expression in breast cancer (Galsgaard et al., 2009). Although both 
mAb 1A2B1 and pAb H-300 produced better IHC staining than the other 
antibodies tested, the authors determined that 1A2B1 was more useful 
for IHC applications. Such evaluation is critical for accuracy in clinical 
diagnosis. The mAb 1A2B1 antibody recognize the ectodomain portion 
of the PRLR protein and pAb H-300 antibody was generated against an 
epitope corresponding to amino acids 323–622 mapping at the C-ter-
minus of the human PRLR, as per manufacturer’s information and 
Galsgaard et al. (Galsgaard et al., 2009). 
Because there is little or no information about the evaluation of these 
antibodies in lymphoma, we had to determine the optimal dilution of 
Fig. 1. Tissue and cell line expression of PRLR. 
A–B. IHC detection of PRLR in HRS cells using 
mAb 1A2B1 and pAb H-300, respectively. 
C-E. Immunofluorescence detection of PRLR 
expression using mAb 1A2B1, in HL-derived cell 
lines Hs445, KMH2 and L428, respectively. 
In A and B, negative controls are presented in 
left panels and arrows in right panels point to 
representative classic HRS cells. Scale bar 
=100 μm.   
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each for IHC and ICC. The optimal dilution of antibodies used for either 
IHC or ICC were determined via serial dilution. From this titration 
process, we determined that mAb 1A2B1 works optimally at 1:400 and 
1:100 dilution for ICC and IHC respectively. Similar analyses resulted in 
application of pAb H-300 at 1:200 dilution for IHC. 
3.2. Expression of PRLR in primary Hodgkin’s and Reed-Sternberg cells 
and HL cell lines 
We used the mAb 1A2B1 and pAb H-300 antibodies to study the 
expression of PRLR on histological sections of HL. PRLR positivity was 
seen in all clinical specimen (n = 6 for each of mAb 1A2B1 and pAb H- 
300). The HRS cells were among the cells that overexpressed PRLR 
(Fig. 1a-b). These cells showed similar levels of expression of PRLR 
across clinical specimen for the respective antibody used. However, the 
staining with mAb 1A2B1 appeared stronger. PRLR staining in HRS cells 
appeared to be localized to the cytoplasm and the cell membrane. 
Immunofluorescent staining using the mAb 1A2B1 showed expres-
sion of PRLR in all three HL-derived cell lines (Hs445, KMH2, L428) 
studied (Fig. 1c-e). This antibody detected cell membrane and cyto-
plasmic PRLR expression in Hs445, but predominantly cell membrane 
PRLR signal for KMH2 and L428 cells. A subset of these latter cells also 
displayed subcellular punta, the origins of which remain unclear in these 
cells in this study. However, although the puncta are relatively large, 
other studies showed PRLR can undergo internalization, appearing as 
bright punctate spots in confocal microscopy images (Genty et al., 1994; 
Perrot-Applanat et al., 1997). Every cell within each viewing field 
observed for each cell line appeared to express PRLR. Like the primary 
HRS cells, cell membrane expression of PRLR appeared robust among 
cell lines. 
3.3. Nature of siRNAs and putative PRLR isoforms in HL 
Studies in breast and prostate cancers revealed that there are mul-
tiple putative isoforms of the human PRLR gene (Abramicheva and 
Smirnova, 2019; Griffith et al., 2016; Shemanko, 2016), presumably a 
consequence of alternative splicing and in some instances a result of 
mutations. As a consequence, we conducted a search to determine the 
putative predicted isoforms or transcript variants associated with PRLR 
siRNA used in this study. siRNA J-006304-07 (sequence: 
CCGCUAAACCCUUGGAUUA) was mapped to transcript variants tran-
script variant 1, 6, X1, X2, X3, X4, X5, X6, delta S1 precursor. siRNA 
J-006304-08 sequence UCAGAUACCUAGUGACUUC was associated 
with transcript variant transcript variant 1, 2, 3, 4, 5, 6, 7, X1, X2, X3, 
X4, X5, X6, delta S1 precursor, delta 4-SF 1B, intermediate isoform, 
short isoforms 1a, 1b, 1c. The predicted transcript variants for siRNA 
J-006304-09 (sequence: CACCAUCACUUGAACAGAA) include tran-
script variant 1, 2, 6, X1, X1, X2, X3, X4, X5, X6, delta S1 precursor, 
intermediate isoform. And siRNA J-006304-10 sequence GCAUGAAU-
GUCCAGACUAC appears to target transcript variant 1, 2, 3, 4, 5, 7, X1, 
X2, X3, X4, X5, X6, delta S1 precursor, delta 4-SF1b truncated, 
delta-4-delta 4/11 truncated, intermediate isoform, and short isoforms 
1a, 1b, 1c. Intriguingly, although the siRNAs showed 100 % similarity 
with the PRLR variants, transcript variant 5 reported for siRNA 
J-006304-08 showed only 73 % similarity. This data suggest that each 
siRNA used in the PRLR knockdown experiments may target multiple 
isoforms. 
3.4. siRNA knockdown of PRLR reduced cell growth 
PRLR overexpression has been implicated in growth and survival of 
cancer cells. Therefore, we studied whether PRLR expression influences 
growth of HL, in vitro. Cells treated with 10 μM of siRNA to PRLR for 
48 h showed loss of immunofluorescent signal and decreased levels of 
PRLR transcripts compared to untreated or NT_siRNA controls (Hs445, 
p < 0.05; KMH2, p < 0.05; L428, p < 0.007), indicating decreased 
expression of the protein (Fig. 2a-c). In these experiments, the Ct values 
for PRLR in parental Hs445 were 24.19, 24.97, 23.81, for KMH2 these 
values were 25.18, 23.97, 24.91, and for L428, 24.58, 24.69, 24.91. 
These values were comparable to those generated from cells treated with 
NT_siRNA and from cells treated with lipofectamine reagent alone. 
One-way ANOVA on WST-1 cell proliferation data showed statisti-
cally significant difference in mean cell growth between NT_siRNA and 
PRPL_siRNA treatment for each cell line of Hs445 (p < 0.02), KMH2 
(p < 0.001) and L428 (p < 0.001) [Fig. 2d]. Similar results were also 
observed for trypan blue exclusion assay and hemocytometry: Hs445 
(p < 0.008) KMH2 (p < 0.005) and L428 (p < 0.002) [Fig. 2e]. These 
results indicated that PRLR may be involved in growth of HL. 
3.5. Expression of PRL by HL cell lines 
Although PRL has been shown to be non-mitogenic to lymphoma 
cells (Matera et al., 2000) PRLR_siRNA-induced decreased growth of HL 
cell lines suggest a putative PRLR-dependent growth mechanism. As PRL 
contained in FBS does not significantly activate human PRLR (Utama 
et al., 2009) we studied HL cell lines for PRL expression using qPCR to 
gain insight into a putative PRL-PRLR axis autocrine growth mechanism. 
The average Ct value for each cell line was 26.82, 28.58, and 24.79 for 
Hs445, KMH2, and L428, respectively. Future studies are needed to 
determine whether PRL is important for growth of HL cells via PRLR 
activation. 
4. Discussion 
The overexpression of hormone receptors has been reported for a 
growing number of cancer types. Such receptors include those for 
growth hormone, estrogens, androgens, and prolactin. Here, we offer 
brief insights into the involvement of PRLR in HL. The IHC analyses 
showed that PRLR is overexpressed by primary HRS cells, using two 
different antibodies. 
We also showed that PRLR is expressed by HL-derived cell lines 
Hs445, KMH2, and L428, using immunofluorescent staining. As with the 
primary HRS cells, robust cell membrane expression of PRLR was 
detected in the cell lines and the expression pattern appeared in almost 
100 % of the cells in the microscopic viewing fields of all three cell lines. 
Cell line expression of PRLR was depleted with siRNA treatment, which 
also reduced cell growth. In addition, qPCR showed varying levels cell 
line expression of PRL, one of the cognate ligands of PRLR, indicating a 
putative autocrine mechanism of cell growth, which warrants further 
research. 
Although not shown in our data, PRLR signaling occurs predomi-
nantly via the JAK2/STAT5 signaling pathway. Therefore, PRLR may be 
one of several JAK2-STAT5 dependent receptors aberrantly active in HL 
(Martini et al., 2008; Scheeren et al., 2008). Activated JAK2/STAT5 
mediates the action of a multiple cytokines contributing to increased 
cytokine release, inflammation and pathogenesis, in HL. For example, 
interleukin-21 (IL-21) which is highly expressed by HRS cells, activates 
STAT5 in HL lymphomagenesis (Scheeren et al., 2008) and mediates the 
recruitment of regulatory T cells (Treg) via STAT3 activation (Lamp-
recht et al., 2008). Treg infiltration in the HL tumor microenvironment 
may be used to predict outcome (Alvaro et al., 2005). Other putative 
PRLR-dependent signaling cascades include those related to cell prolif-
eration (e.g. RAS/RAF/MAPK) (Das and Vonderhaar, 1996), 
anti-apoptosis (Ramirez de Arellano et al., 2015) and cell motility (e.g. 
P13-K) (Maus et al., 1999). Although these signaling cascades are also 
deregulated in HL (Aravinth et al., 2019; Wallentine et al., 2007), 
further studies will be needed to determine if their activities are in part, 
PRLR-dependent in this B cell malignancy. 
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